Leukemia, Myelomonocytic, Acute × Peripheral Blood Stem Cell Transplantation × Clear all Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
Phase 2 Completed
60 enrolled 9 charts
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
Phase 2 Completed
17 enrolled 11 charts
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 15 charts
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
Phase 1 Terminated
10 enrolled
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Withdrawn
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
1 enrolled 5 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
Phase 2 Completed
51 enrolled
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
Phase 3 Unknown
2,000 enrolled
Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission
Phase 2 Completed
45 enrolled
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
720 enrolled
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
Phase 3 Completed
500 enrolled
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
61 enrolled
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
Phase 3 Unknown
1,520 enrolled
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Phase 3 Unknown
2,000 enrolled
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
Phase 2 Unknown
60 enrolled